Analytical Data
-
Gene name
ACVR1
- Application
-
Alternative Names
ACVR1；ACVRLK2；Activin receptor type-1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q04771
-
Expression Region
147-509aa
-
AA Sequence
RKFKRRNQERLNPRDVEYGTIEGLITTNVGDSTLADLLDHSCTSGSGSGL PFLVQRTVAHQITLLECVGKGRYGEVWRGSWQGENVAVKIFSSRDEKSWF RETELYNTVMLRHENILGFIASDMTSRHSSTQLWLITHYHEMGSLYDYLQ LTTLDTVSCLRIVLSIASGLAHLHIEIFGTQGKPAIAHRDLKSKNILVKK NGQCCIADLGLAVMHSQSTNQLDVGNNPRVGTKRYMAPEVLDETIQVDCF DSYKRVDIWAFGLVLWEVARRMVSNGIVEDYKPPFYDVVPNDPSFEDMRK VVCVDQQRPNIPNRWFSDPTLTSLAKLMKECWYQNPSARLTALRIKKTLT KIDNSLDKLKTDC
-
Molecular Weight
67 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ACVR1 (Activin A receptor type I) is a crucial component of the bone morphogenetic protein (BMP) signaling pathway, primarily associated with the regulation of bone and soft tissue development. Mutations in the ACVR1 gene have been linked to several disorders, most notably Fibrodysplasia Ossificans Progressiva (FOP), a rare genetic condition characterized by abnormal bone growth in soft tissues. The study of recombinant ACVR1 proteins has gained significant interest in the fields of developmental biology and regenerative medicine, as understanding the signaling mechanisms involves deciphering how ACVR1 interacts with its ligands. Recombinant ACVR1 proteins can be used to probe the functional assays necessary for identifying potential therapeutic targets and for exploring the pathway's role in ectopic bone formation. Furthermore, investigations into the binding affinities and functional consequences of ACVR1 mutations have implications for drug design aimed at inhibiting aberrant signaling pathways associated with FOP and other skeletal disorders. Thus, research on ACVR1 recombinant proteins not only enhances our understanding of fundamental biological processes but also holds promise for advancing treatment strategies in conditions related to abnormal bone growth.
